VENTRIPOINT Aktie

 

  Toronto, Ontario – TheNewswire - June 17, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has entered into an advisory agreement with Fournel Advisory (“Fournel”) to provide the Company with financial advisory, business development and M&A services for one year to accelerate the commercialization of Ventripoint's AI-powered, heart-scanning technology. Under the terms of the agreement the Company shall pay a cash fee and provide Fournel an option to purchase 265,000 common shares at the market price on June 11, 2025 of $0.11, subject to TSX Venture Exchange approval.   Strategic Advisory   Fournel Advisory is a Paris-based consulting firm dedicated to supporting entrepreneurs and business leaders across Small and Mid-Cap markets. Since 2013, Fournel has specialized in M&A advisory, fundraising, and special situations, both in France and internationally. With a strong focus on the Healthcare ...

    Toronto, Ontario – TheNewswire – June 17, 2025 - Ventripoint Diagnostics Ltd. (“Ventripoint ” or the “ Corporation ”) (TSXV:VPT, OTC:VPTDF) is providing an update on options.  On March 12, 2025, the Corporation issued 500,000 option grants at $0.15 and 500,000 option grants at $0.20 to contractors to the Corporation.  These option grants vested over 4 months and had a term of two years.  On June 2, 2025, the Corporation issued 2,000,000 option grants at $0.10 to employees, consultants and advisors.  The option grants vested from immediately to over 3 years and had a term for two to ten years.  On June 12, 2025, the Corporation 1,635,000 option grants at $0.10 to employees, consultants and advisors. The option grants vested from immediately to over 3 months and had a term for two years.  None of the above option grants were awarded to directors of officers of the Corporation.   Since the last update (see NR February 11, 2024), a total of 3,119,450 options were exercised wit...

  Toronto, Ontario – TheNewswire – May 28, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce its participation in the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) being held on May 28th-31st 2025 in Hamburg, Germany.   The AEPC is a network of specialists committed to the practice and advancement of Congential Cardiology and closely related fields. Since its founding in 1963 AEPC has grown to become the largest global association in congenital cardiology with over 1,000 members. We are excited to be part of this international community and to work with its members to enhance cardiac care.   This year's meeting is hosted by the local organising committee from the University Heart & Vascular Center Hamburg, Children's Heart Medicine and Adults with Congenital Heart Disease. Ventripoint is exhibiting at the meeting and we look forward to seeing our customers, co...

  Toronto, Ontario – TheNewswire - April 30, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has increased the depth of its commercial experience with the addition of Stuart Gall to the company's Business Advisory Board to provide advice and guidance on the commercialization of Ventripoint's AI-powered, heart-scanning technology by hospitals and clinics around the world.   With its proprietary VMS+™ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption   A seasoned health technology executive, Stuart is Chief Executive Officer of Intelligent Ultrasound   (AIM: MED), a company that develops artificial intelligence-based clinical image ...

  Toronto, Canada — April 10, 2025 — TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update.   Dear Shareholders,   With the conclusion of the first quarter we are pleased to provide an update on advancements at Ventripoint and to express our ongoing appreciation for your support. Since our last update the Ventripoint team has maintained its focus on positioning the company to achieve sales and advance towards its growth phase.   Technology and Product Development   Building on the successful development of VMS+ v3.2, which featured our groundbreaking magnet-free sensors, the team completed the verification and validation of VMS+™ v4.0 and submitted applications to regulatory authorities for approval to market the product.   In the latter half of 2024 we received a Medical Device License from Health Canada. This was followed...

  Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company's ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO.   Dr. Coutin was part of the partnering team at AbCellera which built industry-leading capabilities through partnerships with the top tier of biotech and pharma industry partners. His experience includes leading the Venture and core programming team at Creative Destruction Lab, where, with his team, he delivered an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.   “Nic has experience and a strong understanding of translational programs.” said Ventripoint's CEO Hugh MacNaught. “His experience supporting the advanc...

      Toronto, Ontario, April 3, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF)  announces that it has made an application to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of a total of 2,845,771 common share purchase warrants (the “Warrants”) exercisable at $0.30. The Warrants were originally issued by the Company in connection with a private placement financing made to purchasers' resident in Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exempt Distributions, which closed in two tranches on October 17, 2024 and November 12, 2024. (see press releases on August 29, 2024, September 17, 2024, October 15, 2024 and November 14, 2024).   An aggregate of 2,351,730 Warrants issued October 17, 2024 and expiring April 17, 2025 and an aggregate of 494,041 Warrants issued November 12, 2024 and expiring May 12, 2024 will ...

    Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0. This latest advancement of Ventripoint's proprietary technology, VMS+ 4.0, which recently received U.S. FDA 510(k) clearance, delivers a number of significant enhancements including: AI-assisted automated point placement to improve user workflow efficiency  User tools to assist with analysis of the cardiac views  Enhanced visualization tools  Measurements generated from the 3D wire mesh:   ED Volume,   ED Volume Index,   ES Volume,   ES Volume Index,   Ejection Fraction,   Cardiac Output,   Cardiac Index,   Stroke Volume,   Stroke Volume Index.  Reporting of all measurements and derived parameters     The VMS+ system connects...

  Toronto, Ontario, March 21, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces the closing of its previously announced (see press release of March 14, 2025) non-brokered private placement (the “Offering”) of unsecured convertible debenture units (“Units”), subject to final TSXV Venture Exchange (the “Exchange”) acceptance. The Corporation has issued 500 Units for aggregate gross proceeds of $500,000.   Each Unit is comprised: of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation; and 7,143 common share purchase warrants (“Warrants”).   The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.14 per Common Share (the “Conversion Price”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common ...

  Toronto, Ontario – TheNewswire - March 14, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “Offering”) of unsecured convertible debenture units (“Units”) subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) and 7,143 common share purchase warrants (“Warrants”). Depending on market conditions, the Corporation may increase the size of the Offering, subject to approval of the Exchange.   The Debentures will be convertible into Common Shares of the Company at the option of the holder at any time prior to maturity at a conversion price of $0.14 per Common Share (the “Conversion Price”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.18.   Th...

  Toronto, Ontario  - TheNewswire - February 27, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for the VMS+™ 4.0 Automated Radiological Image Processing Software/System. This latest advancement of Ventripoint's proprietary technology, VMS+ 4.0,  delivers a number of significant enhancements including: AI-assisted automated point placement to improve user workflow efficiency  Magnet-free sensors enabling more efficient pairing and improved workflow   User tools to assist with analysis of the cardiac views  Enhanced visualization tools  Measurements generated from the 3D wire mesh:   ED Volume,   ED Volume Index,   ES Volume,   ES Volume Index,   Ejection Fraction,   Cardiac Output,   Cardiac Index,   Stroke Volume,   Stroke Volume Index.  eporting of all measurements and derived parameters   In addition, th...

    Toronto, Ontario – TheNewswire – February 11, 2024 - Ventripoint Diagnostics Ltd. (“Ventripoint ” or the “ Corporation ”)(TSXV:VPT, OTC:VPTDF) announces that on January 20, 2025, the Corporation granted an aggregate of 4,015,000 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of $0.10 and terms of between 2 (two) to 10 (ten) years, vesting from immediately to over a 3 (three) year period. Of these option grants, 200,000 were awarded to directors and an additional 325,000 were awarded to officers some of which are also directors of the Corporation.     These annual option grants are an important part of incentivizing stakeholders to drive value in the Corporation.   Since the last update (see NR September 9, 2024), a total of 153,200 options were exercised with a weighted average price of approximately $0.13 per share for gross proceeds to the Corporation of $19,310.  There are currently 11,762,750 option grants ...

  Toronto, Ontario – TheNewswire - February 10, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, (TSXV:VPT) announces, further to its press release dated December 17, 2024 and January 20, 2025 announcing the closing of the first and second tranches of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17, 2024 and December 20, 2024 press releases) (the “Offering”) of unsecured convertible debentures (“Debentures”) which raised gross proceeds of $341,000 and $169,000 respectively, the closing of the third tranche of  the Offering with the issuance of an additional $87,000 principal amount Debentures.   The Debentures mature on June 28, 2027. The principal amount of each $1,000 of Debenture will be convertible, at the option of the holder, into common shares of the Corporation (“Common Share”) at a conversion price of CDN$0.10 for the first year of the term, CDN$0.15 for the second year of the term and at CDN$0.25 thereaft...

  Toronto, Ontario – TheNewswire - January 30, 2025  – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has significantly bolstered its commercial capability with the addition of Karl Pringle to the company's Business Advisory Board, to accelerate sales of Ventripoint's AI-powered, heart-scanning technology by hospitals and clinics around the world.   With its proprietary VMS+ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption   A seasoned global health technology executive, Karl has a proven passion for driving enterprise-level digital transformation initiatives, with extensive experience in the healthcare space. He is adept at building hig...

  Toronto, Canada — TheNewswire –-- January 23, 2025 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update.   Dear Shareholders,   Further to the update that was provided in December I am pleased to share our outlook and objectives for 2025.     Technology and Product Development   Last year represented significant advances with the development of VMS+3.2 and VMS+4.0, and the granting of CE mark and Health Canada Medical Device License for VMS+4.0. This morning we announced the provision of supplemental information to FDA to support our submission for 510(k) clearance and anticipate a response prior to the end of February.   Looking forward we will continue to refine and enhance VMS+, but the fundamental development activities are completed and our focus is turning to additional cardiac indications and improving the integration of VMS+...

Updates to submission of VMS+ 4.0 provided to FDA on January 17, 2025  Ventripoint will market new advances in USA after FDA clearance  Toronto, Ontario – TheNewswire - January 21, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has reached another development milestone by updating the submission of its next generation of software, VMS+ 4.0, to the U.S. Food and Drug Administration (“FDA”) for clearance.  The update addresses questions regarding cybersecurity and AI. This latest advancement of Ventripoint's proprietary technology, VMS+ 4.0, delivers two significant enhancements to improve clinical workflows AI-assisted echocardiogram image analysis  Simplified sensors pairing workflow.  These new improvements are in addition to the benefits of VMS+ 3.0 Full-scope use so all patient groups can be easily scanned and assessed.  Magnet-free sensors increasing the scope of patients who can benefit  Vendor-neutral interfacing ...

  Toronto, Ontario – TheNewswire - January 20, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces, further to its press release dated December 17, 2024 announcing the closing of the first tranche of its non-brokered private placement (see November 6, 2024, December 9, 2024, December 17, 2024 and December 20, 2024 press releases) (the “Offering”) of unsecured convertible debentures (“Debentures”) which raised gross proceeds of $341,000, the closing of the second tranche of  the Offering with the issuance of an additional $169,000 principal amount Debentures.   The Debentures mature on June 28, 2027. The principal amount of each $1,000 of Debenture will be convertible, at the option of the holder, into common shares of the Corporation (“Common Share”) at a conversion price of CDN$0.10 for the first year of the term, CDN$0.15 for the second year of the term and at CDN$0.25 thereafter. (the “Conversion Price”),   The Debentures bear...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

  Toronto, Ontario – TheNewswire - January 10, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces it will satisfy debenture interest payment obligation with the issuance of common shares, subject to TSX Venture Exchange (“TSXV”) approval. The Corporation will issue an aggregate of up to 83,864 common shares (“Shares”) for the payment of an aggregate of $9,225.20 of interest on certain outstanding Convertible Debentures issued by the Corporation on June 28, 2024. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11, subject to the approval of TSXV and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   Ventripoint also announces it has received TSXV approval to issue an aggregate of 32,769 common shares to settle an aggregate of $3,276 of interest in respect of conv...

  Toronto, Ontario, Dec 20, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“TSXV” or the “Exchange”) to extend its previously announced non-brokered private placement (“Offering”) of unsecured convertible debentures (“Debentures”). (See press releases dated November 6, 2024, December 9, 2024 and December 17, 2024).   On December 16, 2024, Ventripoint issued an aggregate of $341,000 principal amount Debentures with an issue price of $1,000 principal amount per Debenture pursuant to the Offering.   The principal amount of each $1,000 of Debenture will be convertible, at the option of the holder, into common shares of the Corporation (“Common Share”) at a conversion price of CDN$0.10 for the first year of the term, CDN$0.15 for the second year of the term and at CDN$0.25 thereafter. (the “Conversion Price”),   The Debentures bear simple interest at an annual ...